In the first installment of this series, Juan Montoya, MD, discusses the results of the phase 3 pivotal trial of a polyethylene glycol-based hydrogel spacer, reviews real-world data on this product, and provides insights on the evolving practice standards for perirectal spacing in prostate cancer.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.